Table 1 A review of CAR T therapy for humans patients with SLE:
From: CAR T cell therapy for refractory pediatric systemic lupus erythematosus: a new era of hope?
Author | Number of patients | Duration of disease (mean) | Disease manifestations | LN class | Previous treatment | Follow up | Side effects |
|---|---|---|---|---|---|---|---|
Mougiakakos | 1 | Approximately 2 years | LN, pericarditis, pleurisy, rash, arthritis, and a history of Libman–Sacks endocarditis | Class IIIa | Hydroxychloroquine, High-dose glucocorticoids, CYC, MMF, Tacrolimus, Belimumab, and Rituximab | 44 days after infusion reported | None reported |
Zhang | 1 | 20 years | SLE features not reported; also had stage IV diffuse large B cell lymphoma | N/A | Prior SLE treatment not reported; R-CHOP for DLBCL | 37 weeks | None reported |
Mackensen | 5 | 1–9 years (4.6) | LN, carditis, lung disease, and arthritis. No CNS disease. | Class III, IV, or III/V in all 5 patients | Pulsed glucocorticoids (5/5), hydroxychloroquine (5/5),MMF (5/5), belimumab (5/5), azathioprine (2/5), and CYC (3/5) | 5–17 months, mean 9.8 months | CRS grade 1 (fever) in 3 patients |
Taubmann | 1 | Less than one year | Lupus nephritis, serositis, and concern for cerebritis | Class IV | Tacrolimus, Belimumab, CYC, and Rituximab | More than 150 days | None reported |
Zhang | 12 | Not reported | Not reported | Not reported | Rituximab and Belimumab | 45–524 days | Grade 4 hematologic toxicity (11/12); Grade 3 hematologic toxicity (1/2) 2 pts with neocoronavirus; 1 patient with GI infection; 1 patient with pulmonary infection |